Quotient Sciences Conducts Integrated Translational Pharmaceutics® Program in U.S. With Druggability Technologies
6 / 50 articles displayed
Acquisition
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.
News
Quotient Sciences, the innovative provider of early phase drug development services, is pleased to announce that Chief Compliance Officer, Simon Lee, has been elected as Secretary of the European CRO Federation (“EUCROF”).
Awards
Quotient Sciences, the unique and innovative provider of drug development services, today announced it has received a British Private Equity & Venture Capital Association (BVCA) Management Team Award.
Growth
Quotient Sciences, the Translational Pharmaceutics® company, a leading provider of early stage and specialist drug development services, today announced the expansion of its Data Sciences function with relocation to a larger office, staying in Edinburgh.
Association
Quotient are delighted to host a gathering of inhaled medicine experts at the next European Pharmaceutical Aerosol Group (EPAG) meeting.
Showcase
Quotient Sciences is holding a series of formulation development and drug delivery seminars this June and July. The seminars will take place at major life science hubs in the UK and USA, and will address the most pressing challenges currently faced by pharmaceutical and biotechnology companies in early drug development.
